Percheron Therapeutics Limited

Formally known as Antisense Therapeutics, Percheron Therapeutics Limited is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases.

The company’s lead program is ATL1102, an antisense oligonucleotide targeting the CD49d receptor. ATL1102 is currently the subject of an ongoing international phase IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy (DMD), for which data is expected in 2H CY2024.

The company previously reported promising results from an exploratory phase IIa study of in the same population and has been awarded orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA.

Company news

We help investors gain insights into your company through high quality research reports.

We provide a full suite of corporate access services.

 
 
 
Corporate Connect Research

Level 7, 7 Macquarie Place
Sydney NSW 2000
Australia

Email us

Contact us

9 + 14 =